Latent Tuberculosis Infection Detection Market Size, Share, Trends, Growth Outlook

Latent Tuberculosis Infection Detection Market is estimated to increase at a growth rate of 5.9% CAGR over the forecast period from 2024 to 2030.

The global Latent Tuberculosis Infection Detection Marketstudy analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Test Type (Tuberculin Skin Test (TST), Interferon Gamma Released Assay (IGRA)), By Application (Household Contacts with Pulmonary TB, PLHIV, Others), By End-user (Diagnostic Laboratories, Hospitals/clinics, Academic & Research Institutions).

An introduction to Latent Tuberculosis Infection Detection Market in 2024

The Latent Tuberculosis Infection Detection market in 2024 addresses the global challenge of identifying individuals with latent tuberculosis infection (LTBI), a condition where individuals harbor Mycobacterium tuberculosis without showing symptoms of active tuberculosis. Timely detection and treatment of LTBI are crucial for preventing the progression to active tuberculosis and reducing transmission rates. This market encompasses a range of diagnostic tests and screening tools, including interferon-gamma release assays (IGRAs), tuberculin skin tests (TSTs), and molecular assays, designed to detect LTBI accurately and efficiently. Factors such as the high prevalence of tuberculosis in certain regions, increasing efforts for tuberculosis elimination, and advancements in diagnostic technologies drive market growth. Collaboration between diagnostic companies, public health agencies, and healthcare providers facilitates innovation in LTBI detection methods, leading to improved sensitivity, specificity, and accessibility of diagnostic tests.

Latent Tuberculosis Infection Detection Market Trend: Increased Emphasis on Early Detection and Treatment

One prominent trend in the latent tuberculosis infection (LTBI) detection market is the increased emphasis on early detection and treatment of latent TB infection. With the global efforts to eliminate tuberculosis (TB) as a public health threat, there is a growing recognition of the importance of identifying and treating individuals with latent TB infection to prevent the progression to active TB disease. This trend reflects a shift towards proactive TB control strategies, driven by the need to reduce TB transmission, morbidity, and mortality rates worldwide.

Latent Tuberculosis Infection Detection Market Driver: High TB Burden and Risk of Transmission in High-Risk Populations

A significant driver fueling the growth of the latent tuberculosis infection detection market is the high burden of TB and the risk of transmission in high-risk populations. TB remains a major global health challenge, particularly in regions with high prevalence rates and limited access to healthcare resources. Individuals at high risk of TB exposure, such as close contacts of TB patients, healthcare workers, and immunocompromised individuals, require regular screening and testing for latent TB infection to identify cases early and initiate appropriate treatment. Additionally, the growing population of immunocompromised individuals, including those living with HIV/AIDS or receiving immunosuppressive therapies, underscores the need for accurate and sensitive diagnostic tools for latent TB infection detection.

Latent Tuberculosis Infection Detection Market Opportunity: Development of Point-of-Care Testing Solutions

An emerging opportunity in the latent tuberculosis infection detection market lies in the development of point-of-care testing solutions. Traditional methods for diagnosing latent TB infection, such as tuberculin skin tests (TST) and interferon-gamma release assays (IGRAs), may require multiple visits to healthcare facilities and laboratory processing, leading to delays in diagnosis and treatment initiation. There is a growing demand for rapid and convenient point-of-care tests that can accurately detect latent TB infection in resource-limited settings, community clinics, and primary care settings. By developing innovative point-of-care testing solutions, stakeholders can improve access to timely diagnosis and treatment for latent TB infection, particularly in underserved populations and regions with high TB burden. This presents an opportunity to address unmet clinical needs, enhance TB control efforts, and contribute to global TB elimination goals.

Latent Tuberculosis Infection Detection Market Market Segmentation

By Test Type
Tuberculin Skin Test (TST)
Interferon Gamma Released Assay (IGRA)
By Application
Household Contacts with Pulmonary TB
PLHIV
Others
By End-User
Diagnostic Laboratories
Hospitals/clinics
Academic & Research Institutions

Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Latent Tuberculosis Infection Detection Market Companies

Abbott
Becton, Dickinson, and Company
bioMerieux
F. Hoffmann-La Roche Ltd.
Lionex GmbH
Oxford Immunotec USA Inc
Sanofi
Serum Institute of India Pvt. Ltd

Reasons to Buy the Latent Tuberculosis Infection Detection Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Latent Tuberculosis Infection Detection Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Latent Tuberculosis Infection Detection Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Latent Tuberculosis Infection Detection Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Latent Tuberculosis Infection Detection Market Size Outlook, $ Million, 2021 to 2030
3.2 Latent Tuberculosis Infection Detection Market Outlook by Type, $ Million, 2021 to 2030
3.3 Latent Tuberculosis Infection Detection Market Outlook by Product, $ Million, 2021 to 2030
3.4 Latent Tuberculosis Infection Detection Market Outlook by Application, $ Million, 2021 to 2030
3.5 Latent Tuberculosis Infection Detection Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Latent Tuberculosis Infection Detection Industry
4.2 Key Market Trends in Latent Tuberculosis Infection Detection Industry
4.3 Potential Opportunities in Latent Tuberculosis Infection Detection Industry
4.4 Key Challenges in Latent Tuberculosis Infection Detection Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Latent Tuberculosis Infection Detection Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Latent Tuberculosis Infection Detection Market Outlook by Segments
7.1 Latent Tuberculosis Infection Detection Market Outlook by Segments, $ Million, 2021- 2030
By Test Type
Tuberculin Skin Test (TST)
Interferon Gamma Released Assay (IGRA)
By Application
Household Contacts with Pulmonary TB
PLHIV
Others
By End-User
Diagnostic Laboratories
Hospitals/clinics
Academic & Research Institutions

8 North America Latent Tuberculosis Infection Detection Market Analysis and Outlook To 2030
8.1 Introduction to North America Latent Tuberculosis Infection Detection Markets in 2024
8.2 North America Latent Tuberculosis Infection Detection Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Latent Tuberculosis Infection Detection Market size Outlook by Segments, 2021-2030
By Test Type
Tuberculin Skin Test (TST)
Interferon Gamma Released Assay (IGRA)
By Application
Household Contacts with Pulmonary TB
PLHIV
Others
By End-User
Diagnostic Laboratories
Hospitals/clinics
Academic & Research Institutions

9 Europe Latent Tuberculosis Infection Detection Market Analysis and Outlook To 2030
9.1 Introduction to Europe Latent Tuberculosis Infection Detection Markets in 2024
9.2 Europe Latent Tuberculosis Infection Detection Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Latent Tuberculosis Infection Detection Market Size Outlook by Segments, 2021-2030
By Test Type
Tuberculin Skin Test (TST)
Interferon Gamma Released Assay (IGRA)
By Application
Household Contacts with Pulmonary TB
PLHIV
Others
By End-User
Diagnostic Laboratories
Hospitals/clinics
Academic & Research Institutions

10 Asia Pacific Latent Tuberculosis Infection Detection Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Latent Tuberculosis Infection Detection Markets in 2024
10.2 Asia Pacific Latent Tuberculosis Infection Detection Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Latent Tuberculosis Infection Detection Market size Outlook by Segments, 2021-2030
By Test Type
Tuberculin Skin Test (TST)
Interferon Gamma Released Assay (IGRA)
By Application
Household Contacts with Pulmonary TB
PLHIV
Others
By End-User
Diagnostic Laboratories
Hospitals/clinics
Academic & Research Institutions

11 South America Latent Tuberculosis Infection Detection Market Analysis and Outlook To 2030
11.1 Introduction to South America Latent Tuberculosis Infection Detection Markets in 2024
11.2 South America Latent Tuberculosis Infection Detection Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Latent Tuberculosis Infection Detection Market size Outlook by Segments, 2021-2030
By Test Type
Tuberculin Skin Test (TST)
Interferon Gamma Released Assay (IGRA)
By Application
Household Contacts with Pulmonary TB
PLHIV
Others
By End-User
Diagnostic Laboratories
Hospitals/clinics
Academic & Research Institutions

12 Middle East and Africa Latent Tuberculosis Infection Detection Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Latent Tuberculosis Infection Detection Markets in 2024
12.2 Middle East and Africa Latent Tuberculosis Infection Detection Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Latent Tuberculosis Infection Detection Market size Outlook by Segments, 2021-2030
By Test Type
Tuberculin Skin Test (TST)
Interferon Gamma Released Assay (IGRA)
By Application
Household Contacts with Pulmonary TB
PLHIV
Others
By End-User
Diagnostic Laboratories
Hospitals/clinics
Academic & Research Institutions

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Abbott
Becton, Dickinson, and Company
bioMerieux
F. Hoffmann-La Roche Ltd.
Lionex GmbH
Oxford Immunotec USA Inc
Sanofi
Serum Institute of India Pvt. Ltd
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Test Type
Tuberculin Skin Test (TST)
Interferon Gamma Released Assay (IGRA)
By Application
Household Contacts with Pulmonary TB
PLHIV
Others
By End-User
Diagnostic Laboratories
Hospitals/clinics
Academic & Research Institutions